Host-directed therapies in pulmonary tuberculosis: Updates on anti-inflammatory drugs

JM Cubillos-Angulo, BMF Nogueira, MB Arriaga… - Frontiers in …, 2022 - frontiersin.org
Tuberculosis (TB) is a lethal disease and remains one of the top ten causes of mortality by
an infectious disease worldwide. It can also result in significant morbidity related to …

Host-directed therapies for tuberculosis

EK Jeong, HJ Lee, YJ Jung - Pathogens, 2022 - mdpi.com
Tuberculosis (TB) is one of the leading causes of death worldwide, consistently threatening
public health. Conventional tuberculosis treatment requires a long-term treatment regimen …

Host-directed therapeutic strategies for tuberculosis

A Kolloli, S Subbian - Frontiers in medicine, 2017 - frontiersin.org
Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb), remains a leading cause of
morbidity and mortality in humans worldwide. Currently, the standard treatment for TB …

Host-directed therapy as a novel treatment strategy to overcome tuberculosis: targeting immune modulation

S Ahmed, R Raqib, GH Guðmundsson, P Bergman… - Antibiotics, 2020 - mdpi.com
Tuberculosis (TB) is one of the leading causes of mortality and morbidity, particularly in
developing countries, presenting a major threat to the public health. The currently …

Opportunities and challenges for host-directed therapies in tuberculosis

M Sachan, A Srivastava, R Ranjan… - Current …, 2016 - ingentaconnect.com
Background: Tuberculosis (TB) ranks alongside the human immunodeficiency virus (HIV) as
cause of death due to an infectious disease. Recently, host-targeted therapies (HDT) have …

[HTML][HTML] Advances in immunomodulatory strategies for host-directed therapies in combating tuberculosis

S Ayodele, P Kumar, A van Eyk… - Biomedicine & …, 2023 - Elsevier
Tuberculosis (TB) maintains its infamous status regarding its detrimental effect on global
health, causing the highest mortality by a single infectious agent. The presence of resistance …

Potential of immunomodulatory agents as adjunct host-directed therapies for multidrug-resistant tuberculosis

A Zumla, M Rao, E Dodoo, M Maeurer - BMC medicine, 2016 - Springer
Abstract Treatment of multidrug-resistant tuberculosis (MDR-TB) is extremely challenging
due to the virulence of the etiologic strains of Mycobacterium tuberculosis (M. tb), the …

[HTML][HTML] Therapeutic host-directed strategies to improve outcome in tuberculosis

C Young, G Walzl, N Du Plessis - Mucosal immunology, 2020 - Elsevier
Abstract Bacille Calmette-Guérin (BCG) is the only licenced tuberculosis (TB) vaccine, but
has limited efficacy against pulmonary TB disease development and modest protection …

Host directed therapies for tuberculosis: futures strategies for an ancient disease

I Palucci, G Delogu - Chemotherapy, 2018 - karger.com
The emergence and spread of drug-resistant strains of Mycobacterium tuberculosis is
worsening the global threat of tuberculosis (TB). There is a need and urgency for the …

Remembering the host in tuberculosis drug development

DJ Frank, DJ Horne, NK Dutta, MT Shaku… - The Journal of …, 2019 - academic.oup.com
New therapeutics to augment current approaches and shorten treatment duration are of
critical importance for combating tuberculosis (TB), especially those with novel mechanisms …